ExtraLife
Thymosin Alpha-1, LL-37, KPV, PT-141, and DSIP — peptides for immune defense and specialized needs.
Thymosin Alpha-1 (Ta1) is a 28-amino-acid peptide naturally produced by the thymus gland — the organ responsible for training and maturing T-cells. Ta1 is one of the few therapeutic peptides with actual regulatory approval: it is approved in over 35 countries (marketed as Zadaxin) for treating hepatitis B and C, and as an immune adjuvant in cancer therapy. It works by activating dendritic cells, enhancing T-cell maturation, modulating cytokine production (increasing IL-2, IFN-alpha), and improving the immune system's ability to recognize and respond to pathogens and abnormal cells. Research also suggests Ta1 can improve vaccine efficacy in immunocompromised populations, including the elderly. Unlike immunosuppressants, Ta1 is an immunomodulator — it balances immune response rather than simply suppressing or stimulating it.
Thymosin Alpha-1 is one of the most validated immune peptides — approved in 35+ countries for hepatitis and cancer adjunct therapy, it modulates rather than simply boosts immune function. **Research Status**: Strong clinical evidence. FDA-orphan drug designation, approved in 35+ countries (as Zadaxin). Multiple randomized controlled trials for hepatitis B/C and as cancer immunotherapy adjuvant.
LL-37 is the only human cathelicidin-derived antimicrobial peptide. Your body produces it as a first-line defense against bacteria, viruses, and fungi. LL-37 works through multiple mechanisms: it directly disrupts microbial cell membranes (punching holes in bacterial walls), modulates inflammatory responses, promotes wound healing by stimulating angiogenesis and re-epithelialization, and recruits immune cells to sites of infection. Research suggests therapeutic LL-37 may be beneficial for chronic infections, biofilm-associated conditions (such as chronic sinusitis or Lyme disease co-infections), and wound healing. Most evidence is preclinical, though human studies are emerging. LL-37 levels decline with age and vitamin D deficiency — in fact, vitamin D directly regulates LL-37 expression, which is one mechanism by which vitamin D supports immune health.
LL-37 is your body's natural antimicrobial peptide — it directly kills pathogens, modulates inflammation, and promotes wound healing. Its production depends on adequate vitamin D levels. **Research Status**: Limited/emerging evidence for therapeutic use. Well-characterized as an endogenous antimicrobial peptide, but therapeutic applications remain primarily preclinical. No FDA approval for therapeutic LL-37 administration.
KPV is a three-amino-acid fragment (Lys-Pro-Val) derived from alpha-melanocyte stimulating hormone (alpha-MSH). Despite being just three amino acids long, KPV has demonstrated potent anti-inflammatory activity in preclinical research. It inhibits NF-kB signaling — a master switch in inflammatory pathways — and reduces production of pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-1beta. Research has focused on KPV's potential in inflammatory bowel disease (IBD), with animal studies showing reduced intestinal inflammation and improved mucosal healing. Its small size allows oral bioavailability — unusual for peptides — making it a candidate for gut-targeted delivery. KPV has also shown antimicrobial properties against certain bacteria, particularly in the gut environment. Clinical human trial data remain limited, and KPV should be considered investigational.
KPV is a remarkably small yet potent anti-inflammatory peptide — it inhibits the NF-kB master inflammatory switch and shows promise for gut inflammation, with the unusual advantage of oral bioavailability. **Research Status**: Limited/emerging evidence. Preclinical animal studies in IBD models show promise, but human clinical trial data is very limited. Investigational compound.
PT-141 (bremelanotide) is unique among peptides discussed in this curriculum because it is FDA-approved (marketed as Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women. PT-141 works through melanocortin receptors (MC3R and MC4R) in the central nervous system — it acts on the brain rather than the vascular system, distinguishing it from PDE5 inhibitors like sildenafil. This central mechanism means PT-141 addresses desire and arousal at a neurological level, not just blood flow. Clinical trials demonstrated statistically significant improvements in sexual desire and reduced distress related to low libido. Side effects include nausea (in approximately 40% of patients, usually transient), flushing, and headache. PT-141 is not recommended for patients with uncontrolled hypertension or cardiovascular disease. Research into male sexual dysfunction applications is ongoing.
PT-141 is FDA-approved for female HSDD — it uniquely works through brain melanocortin receptors to address desire at a neurological level, not just blood flow like traditional ED medications. **Research Status**: Strong clinical evidence. FDA-approved (as Vyleesi/bremelanotide) for hypoactive sexual desire disorder in premenopausal women. Multiple Phase III randomized controlled trials.
Delta Sleep-Inducing Peptide (DSIP) is a nine-amino-acid neuropeptide first isolated from rabbit brain tissue in 1977 during induced sleep studies. Research suggests DSIP modulates sleep architecture by promoting delta wave (deep sleep) activity without acting as a sedative — a critical distinction. Rather than forcing sleep like benzodiazepines or Z-drugs, DSIP appears to normalize disrupted sleep patterns by modulating cortisol rhythms, ACTH release, and LH/GH secretion timing. Preclinical studies have shown it can reduce the time to fall asleep, increase deep sleep duration, and normalize circadian rhythm disruptions. Some research also suggests anxiolytic and stress-protective properties. However, DSIP research has been inconsistent across studies, with some trials showing strong effects and others showing modest results. Most evidence remains preclinical, and the peptide's exact mechanism of action is still not fully characterized. DSIP should be considered investigational, and any use should be supervised by a qualified physician.
DSIP promotes deep delta-wave sleep by normalizing sleep architecture rather than sedating — but research remains inconsistent, and it should be considered investigational with physician supervision required. **Research Status**: Limited/emerging evidence. Inconsistent results across studies. Mechanism of action not fully characterized. Should be considered investigational.